Artiva Biotherapeutics (ARTV) Interest Expenses (2023 - 2026)
Artiva Biotherapeutics (ARTV) posted quarterly Interest Expenses of $11.7 million for Q1 2026, down 29.36% year-over-year from $16.5 million in Q1 2025, and up 2734.95% quarter-over-quarter from $412000.0 in Q4 2025.
Artiva Biotherapeutics (ARTV) Interest Expenses (2023 - 2026) Analysis & Trends
Artiva Biotherapeutics (ARTV) has reported Interest Expenses for 4 consecutive years, with $11.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Expenses fell 29.36% year-over-year to $11.7 million; the TTM figure through Mar 2026 stood at $11.7 million (down 29.36% YoY), while the FY2025 annual figure was $3.9 million, down 45.5% from the prior year.
- Interest Expenses rose to $11.7 million in Q1 2026 per ARTV's latest filing, from $412000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $17.3 million in Q3 2024 and bottomed at $214000.0 in Q4 2023.
- Historically, Interest Expenses has averaged $9.2 million across 4 years, with a median of $11.7 million in 2026.
- Annual changes were most pronounced in 2024 — Interest Expenses soared 3226.17% — and 2025, when it sank 94.21%.
- Artiva Biotherapeutics' Interest Expenses stood at $214000.0 in 2023, then jumped by 3226.17% to $7.1 million in 2024, then tumbled by 94.21% to $412000.0 in 2025, then jumped by 2734.95% to $11.7 million in 2026.
- Business Quant data shows ARTV's Interest Expenses at $11.7 million in Q1 2026, $412000.0 in Q4 2025, and $1.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Artiva Biotherapeutics | 451.28 Mn | 451.28 Mn | - | 11.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.09 Mn |
| Jun 30, 2026 | 11.09 Mn |
| Mar 31, 2026 | 11.68 Mn |
| Mar 31, 2026 | 11.68 Mn |
| Dec 31, 2025 | 412,000.00 |
| Dec 31, 2025 | 412,000.00 |
| Sep 30, 2025 | 1.84 Mn |
| Sep 30, 2025 | 1.84 Mn |
| Jun 30, 2025 | 15.50 Mn |
| Jun 30, 2025 | 15.50 Mn |
| Mar 31, 2025 | 16.53 Mn |
| Mar 31, 2025 | 16.53 Mn |
| Dec 31, 2024 | 7.12 Mn |
| Dec 31, 2024 | 7.12 Mn |
| Sep 30, 2024 | 17.31 Mn |
| Sep 30, 2024 | 17.31 Mn |
| Jun 30, 2024 | 12.54 Mn |
| Jun 30, 2024 | 12.54 Mn |
| Dec 31, 2023 | 214,000.00 |
| Dec 31, 2023 | 214,000.00 |